Clinical Trial Update: A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for AMN107 in adults with Glivec-intolerant chronic myeloid leukemia or relapsed/refractory Philadelphia chromosome–positive acute lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia Philadelphia Chromosome-positive
• Myelogenous Leukemia

Drugs mentioned

• AMN107 (nilotinib)
• Glivec (imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) | Phase 1, Phase 2 | Status: COMPLETED